325 related articles for article (PubMed ID: 24889535)
1. Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.
Menezes ME; Das SK; Emdad L; Windle JJ; Wang XY; Sarkar D; Fisher PB
Adv Cancer Res; 2014; 121():331-382. PubMed ID: 24889535
[TBL] [Abstract][Full Text] [Related]
2. Recent Advancement in Breast Cancer Research: Insights from Model Organisms-Mouse Models to Zebrafish.
Singhal SS; Garg R; Mohanty A; Garg P; Ramisetty SK; Mirzapoiazova T; Soldi R; Sharma S; Kulkarni P; Salgia R
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296923
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mouse models of breast cancer.
Regua AT; Arrigo A; Doheny D; Wong GL; Lo HW
Cancer Lett; 2021 Sep; 516():73-83. PubMed ID: 34090924
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ.
Namba R; Maglione JE; Young LJ; Borowsky AD; Cardiff RD; MacLeod CL; Gregg JP
Mol Cancer Res; 2004 Aug; 2(8):453-63. PubMed ID: 15328372
[TBL] [Abstract][Full Text] [Related]
5. β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer.
Lahlou H; Muller WJ
Breast Cancer Res; 2011; 13(6):229. PubMed ID: 22264244
[TBL] [Abstract][Full Text] [Related]
6. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
7. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.
Zhu M; Yi M; Kim CH; Deng C; Li Y; Medina D; Stephens RM; Green JE
Genome Biol; 2011 Aug; 12(8):R77. PubMed ID: 21846369
[TBL] [Abstract][Full Text] [Related]
8. Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling.
Shoushtari AN; Michalowska AM; Green JE
Breast Dis; 2007; 28():39-51. PubMed ID: 18057542
[TBL] [Abstract][Full Text] [Related]
9. Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration.
Bray K; Gillette M; Young J; Loughran E; Hwang M; Sears JC; Vargo-Gogola T
Breast Cancer Res; 2013; 15(5):R91. PubMed ID: 24074261
[TBL] [Abstract][Full Text] [Related]
10. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
11. Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer.
Grosset AA; Poirier F; Gaboury L; St-Pierre Y
PLoS One; 2016; 11(11):e0166731. PubMed ID: 27902734
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered mouse models of mammary intraepithelial neoplasia.
Cardiff RD; Moghanaki D; Jensen RA
J Mammary Gland Biol Neoplasia; 2000 Oct; 5(4):421-37. PubMed ID: 14973386
[TBL] [Abstract][Full Text] [Related]
13. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
14. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
Telang N; Katdare M
Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
[TBL] [Abstract][Full Text] [Related]
15. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
16. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
17. Breast tumors: of mice and women.
McDermott SP; Wicha MS
Breast Cancer Res; 2010; 12(3):108. PubMed ID: 20550730
[TBL] [Abstract][Full Text] [Related]
18. Timp3 deficient mice show resistance to developing breast cancer.
Jackson HW; Hojilla CV; Weiss A; Sanchez OH; Wood GA; Khokha R
PLoS One; 2015; 10(3):e0120107. PubMed ID: 25807548
[TBL] [Abstract][Full Text] [Related]
19. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis.
Zhang J; Li Y; Liu Q; Lu W; Bu G
Oncogene; 2010 Jan; 29(4):539-49. PubMed ID: 19881541
[TBL] [Abstract][Full Text] [Related]
20. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential.
Lin M; Ku AT; Dong J; Yue F; Jiang W; Ibrahim AA; Peng F; Creighton CJ; Nagi C; Gutierrez C; Rosen JM; Zhang XH; Hilsenbeck SG; Chen X; Du YN; Huang S; Shi A; Fan Z; Li Y
Oncogene; 2022 Nov; 41(48):5214-5222. PubMed ID: 36261627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
